TMS Co

TMS Co Net Change in Cash

The Net Change in Cash of TMS Co (4891.T) as of Nov 3, 2026 is -665.60 M JPY. In the previous year, Net Change in Cash was -523.68 M JPY — a change of 27.10% (lower).

Net Change in Cash

-665.60 MJPY

YoY

27.10%

Last updated:

Net Change in Cash of TMS Co is 2026 -665.60 M JPY. Net Change in Cash of TMS Co was 2025 -523.68 M JPY. It decreases by 27.10% lower compared to the previous year.

The TMS Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2021
362.85 M JPY
Jan 1, 2022
1.49 B JPY
Jan 1, 2023
986.67 M JPY
Jan 1, 2024
-138.04 M JPY
Jan 1, 2025
-523.68 M JPY
Jan 1, 2026
-665.60 M JPY
The TMS Co Net Change in Cash history
YEARNet Change in CashYoY
-665.60 MJPY+27.10%
-523.68 MJPY+279.38%
-138.04 MJPY-113.99%
986.67 MJPY-33.84%
1.49 BJPY+310.99%
362.85 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Net Change in Cash of TMS Co is -665.60 M JPY in 2026.

Net Change in Cash of TMS Co changed from -523.68 M JPY to -665.60 M JPY, representing a 27.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash TMS Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — TMS Co

All Key Metrics — TMS Co